Geode Capital¡¯s $8.1 Billion Healthcare Stock Investment Portfolio in Q3: JNJ, PFE, MRK, ABT

Wall St. Watchdog reveals information regarding Geode Capital Management��s top holdings in the Healthcare sector for the quarter ending September 30th, 2011. The firm held 426 stocks in the Healthcare sector at the end of the quarter with an aggregate market value of $8.171 billion.

• Johnson & Johnson (NYSE:JNJ): On 06/30/2011, Geode Capital Management reported holding 17,379,247 shares with a market value of $1,156,067,452. This comprised 1.42% of the total portfolio. On 09/30/2011, Geode Capital Management reported holding 18,520,483 shares with a market value of $1,179,569,537. This comprised 1.59% of the total portfolio. The net change in shares for this position over the two quarters is 1,141,236. About Company: Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
• Pfizer Inc. (NYSE:PFE): On 06/30/2011, Geode Capital Management reported holding 50,246,842 shares with a market value of $1,035,084,964. This comprised 1.27% of the total portfolio. On 09/30/2011, Geode Capital Management reported holding 52,738,538 shares with a market value of $932,417,368. This comprised 1.26% of the total portfolio. The net change in shares for this position over the two quarters is 2,491,696. About Company: Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company��s products include prescription pharmaceuticals, non-prescription self-medications, and animal health products such as anti-infective medicines and vaccines.
• Merck & Co. Inc. (NYSE:MRK): On 06/30/2011, Geode Capital Management reported holding 19,586,295 shares with a mark! et value of $691,200,368. This comprised 0.85% of the total portfolio. On 09/30/2011, Geode Capital Management reported holding 20,839,205 shares with a market value of $681,442,019. This comprised 0.92% of the total portfolio. The net change in shares for this position over the two quarters is 1,252,910. About Company: Merck & Co., Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human and animal health products. Merck��s products include a treatment for elevated cholesterol, a treatment for male pattern hair loss, a preventive treatment for osteoporosis, a treatment for hypertension, and a treatment for allergic rhinitis.
• Abbott Laboratories (NYSE:ABT): On 06/30/2011, Geode Capital Management reported holding 9,838,077 shares with a market value of $517,679,601. This comprised 0.63% of the total portfolio. On 09/30/2011, Geode Capital Management reported holding 10,534,774 shares with a market value of $538,748,336. This comprised 0.73% of the total portfolio. The net change in shares for this position over the two quarters is 696,697. About Company: Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company��s products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.
• Bristol-myers Squibb Company (NYSE:BMY): On 06/30/2011, Geode Capital Management reported holding 10,863,169 shares with a market value of $314,597,364. This comprised 0.39% of the total portfolio. On 09/30/2011, Geode Capital Management reported holding 11,581,403 shares with a market value of $363,424,416. This comprised 0.49% of the total portfolio. The net change in shares for this position over the two quarters is 718,234. About Company: Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures and se! lls phar maceutical and nutritional products. The Company��s products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders.
• Amgen Inc. (NASDAQ:AMGN): On 06/30/2011, Geode Capital Management reported holding 6,003,480 shares with a market value of $350,303,049. This comprised 0.43% of the total portfolio. On 09/30/2011, Geode Capital Management reported holding 6,345,915 shares with a market value of $348,771,483. This comprised 0.47% of the total portfolio. The net change in shares for this position over the two quarters is 342,435. About Company: Amgen Inc. discovers, develops, manufactures, and markets human therapeutics based on cellular and molecular biology. The Company focuses its research on secreted protein and small molecule therapeutics, with particular emphasis on neuroscience and cancer. Amgen concentrates on the areas of hematology, cancer, infectious disease, endocrinology, neurobiology, and inflammation.
• Unitedhealth Group Inc. (NYSE:UNH): On 06/30/2011, Geode Capital Management reported holding 6,889,696 shares with a market value of $355,370,532. This comprised 0.44% of the total portfolio. On 09/30/2011, Geode Capital Management reported holding 7,297,324 shares with a market value of $336,552,575. This comprised 0.45% of the total portfolio. The net change in shares for this position over the two quarters is 407,628. About Company: UnitedHealth Group Incorporated owns and manages organized health systems in the United States and internationally. The Company provides employers products and resources to plan and administer employee benefit programs. UnitedHealth also serves the health needs of older Americans, provides specialized care services, and provides health care information and research to providers and payers.
• Medtronic Inc. (NYSE:MDT): On 06/30/2011, Geode Capital Management reported holding 6,788,478 sh! ares wit h a market value of $261,560,049. This comprised 0.32% of the total portfolio. On 09/30/2011, Geode Capital Management reported holding 7,135,047 shares with a market value of $237,168,974. This comprised 0.32% of the total portfolio. The net change in shares for this position over the two quarters is 346,569. About Company: Medtronic, Inc. develops therapeutic and diagnostic medical products. The Company��s principal products include those for bradycardia pacing, tachyarrhythmia management, atrial fibrillation management, heart failure management, heart valve replacement, malignant and non-malignant pain, and movement disorders. Medtronic��s products are sold worldwide.
• Eli Lilly & Co. (NYSE:LLY): On 06/30/2011, Geode Capital Management reported holding 5,558,813 shares with a market value of $208,622,245. This comprised 0.26% of the total portfolio. On 09/30/2011, Geode Capital Management reported holding 5,977,647 shares with a market value of $220,993,617. This comprised 0.3% of the total portfolio. The net change in shares for this position over the two quarters is 418,834. About Company: Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company��s products are sold in countries around the world. Eli Lilly��s products include neuroscience products, endocrine products, anti-infectives, cardiovascular agents, oncology products, and animal health products.
• Baxter International Inc. (NYSE:BAX): On 06/30/2011, Geode Capital Management reported holding 3,620,578 shares with a market value of $216,112,296. This comprised 0.26% of the total portfolio. On 09/30/2011, Geode Capital Management reported holding 3,846,264 shares with a market value of $215,929,259. This comprised 0.29% of the total portfolio. The net change in shares for this position over the two quarters is 225,686. About Company: Baxter International Inc. develops, manufactures, and markets products and technologies relat! ed to he mophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. The Company��s products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors�� offices, and research laboratories.